AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time SYNTAX score feedback from image analysts during intervention period.
Number of subjects: 3245
Study 32452896 — intervention group
Group type: COMPARATOR
Intervention: Control group with SYNTAX scores calculated by treating cardiologists.
Number of subjects: 3245
Study 35162627 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance combined with plyometric training (PB)
Number of subjects: 16
Study 35162627 — intervention group
Group type: COMPARATOR
Intervention: Plyometric training (PT)
Number of subjects: 16
Study 33017565 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Physical Therapy (EPT)
Number of subjects: 220
Study 33017565 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 220
Study 32517123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus ATCC 53103 for 28 days at a dosage of 5 × 10^9 cfu per day
Number of subjects: 45
Study 32517123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus ATCC 53103 for 28 days
Number of subjects: 45
Study 32517123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 33549445 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised Nordic walking (NW)
Number of subjects: 27
Study 33549445 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised walking (W)
Number of subjects: 27
Study 33549445 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 27
Study 32818946 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss programme for 12 weeks
Number of subjects: 889
Study 32818946 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss programme for 52 weeks
Number of subjects: 889
Study 32818946 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance group (10-12 sessions)
Number of subjects: 889
Study 32818946 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief support only)
Number of subjects: 889
Study 35441218 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rice bran supplementation (1 to 5 g/d)
Number of subjects: 0
Study 35441218 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34721259 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-aided stretching device
Number of subjects: 20
Study 34721259 — intervention group
Group type: COMPARATOR
Intervention: Manual stretching
Number of subjects: 20
Study 32816895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab following CRT
Number of subjects: 26
Study 32816895 — intervention group
Group type: COMPARATOR
Intervention: CRT only
Number of subjects: 26
Study 34214479 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg, 4 × 100 mg film‐coated tablets per day for 26 weeks)
Number of subjects: 67
Study 34214479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 34214479 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 67
Study 32047963 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRSS-PSP training
Number of subjects: 24
Study 32047963 — intervention group
Group type: COMPARATOR
Intervention: Conventional model (NON-VR group)
Number of subjects: 24
Study 36152764 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% IV albumin 1.5g/kg weekly infusions
Number of subjects: 48
Study 36152764 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 48
Study 33026700 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab added to lenalidomide and dexamethasone
Number of subjects: 3
Study 33026700 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab added to bortezomib, melphalan, and prednisone
Number of subjects: 3
Study 33026700 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab added to bortezomib, thalidomide, and dexamethasone
Number of subjects: 3
Study 33026700 — intervention group
Group type: COMPARATOR
Intervention: Daratumumab (various combinations)
Number of subjects: 3
Study 35712635 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed cow’s milk protein formula (PHF, 75% carbohydrate as lactose; 12 mg Mg/100 kcal)
Number of subjects: 100
Study 35712635 — intervention group
Group type: COMPARATOR
Intervention: Routine intact protein cow’s milk‐based infant formula (Control, 92% carbohydrate as lactose; 8 mg Mg/100 kcal)
Number of subjects: 100
Study 33470739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Spectral Imaging (DSI) colposcopy
Number of subjects: 417
Study 33470739 — intervention group
Group type: COMPARATOR
Intervention: Regular colposcopy
Number of subjects: 417
Study 33470739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DSI and regular colposcopy
Number of subjects: 417
Study 34980410 — intervention group
Group type: EXPERIMENTAL
Intervention: Human safety claims (with 'Antibiotic‐free' and 'Pathogen‐ and zoonosis‐free')
Number of subjects: 603
Study 34980410 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal welfare claims (with 'No animal breeding' and 'No animal slaughtering')
Number of subjects: 603
Study 34980410 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental impact claims (with '82‐96% reduction of water consumption' and '99% reduction of soil usage')
Number of subjects: 603
Study 34980410 — intervention group
Group type: COMPARATOR
Intervention: No additional information (control)
Number of subjects: 603
Study 32200425 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of diagnostic algorithm
Number of subjects: 224
Study 32200425 — intervention group
Group type: COMPARATOR
Intervention: No algorithm (control group)
Number of subjects: 224
Study 36001840 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative IV TA alone and post‐operative oral TA (n=26)
Number of subjects: 50
Study 36001840 — intervention group
Group type: COMPARATOR
Intervention: Perioperative IV TA plus 48 hours additional oral placebo (n=24)
Number of subjects: 50
Study 34507703 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy (630 nm and 940 nm) at a dose of 6 J/cm2, three times a week for 8 weeks
Number of subjects: 15
Study 34507703 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy (630 nm and 940 nm) at a dose of 8 J/cm2, three times a week for 8 weeks
Number of subjects: 15
Study 34507703 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group) consisting of cleaning with physiological solution and alginate hydrogel dressing, daily for 8 weeks
Number of subjects: 15
Study 33612595 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein polymeric formula
Number of subjects: 55
Study 33612595 — intervention group
Group type: COMPARATOR
Intervention: Control (5% Dextrose)
Number of subjects: 55
Study 33612595 — intervention group
Group type: COMPARATOR
Intervention: Oligomeric formula
Number of subjects: 55
Study 34580032 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (educational approach with 31 deprescribing-related clinical case scenarios delivered through WhatsApp)
Number of subjects: 108
Study 34580032 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 108
Study 34580032 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 35229945 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 308
Study 35229945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 33733965 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% hypertonic glucose (HG)
Number of subjects: 159
Study 33733965 — intervention group
Group type: COMPARATOR
Intervention: 0.2% sodium tetradecyl sulfate (STS)
Number of subjects: 159
Study 32393498 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 404
Study 32393498 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 404
Study 35034949 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, for 20 min)
Number of subjects: 30
Study 35034949 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (2 mA, for 30 s, ramped up, then ramped down)
Number of subjects: 30
Study 33750471 — intervention group
Group type: COMPARATOR
Intervention: Biologic therapy targeting Type 2 inflammatory pathway (e.g., IL-4, IL-5, IL-13, IL-5R, IL-33, IgE)
Number of subjects: 0
Study 32925776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) with 5mg/mL of epinephrine and 40 mL of ropivacaine 0.2%
Number of subjects: 100
Study 32925776 — intervention group
Group type: COMPARATOR
Intervention: Non-FICB (placebo control)
Number of subjects: 100
Study 35608567 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training
Number of subjects: 59
Study 35608567 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance training
Number of subjects: 59
Study 35608567 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 59
Study 36040717 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding THV
Number of subjects: 1644
Study 36040717 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable THV
Number of subjects: 1644
Study 36052812 — intervention group
Group type: EXPERIMENTAL
Intervention: PLEASED intervention (peer-led diabetes self-management support)
Number of subjects: 196
Study 36052812 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study 33710814 — intervention group
Group type: COMPARATOR
Intervention: ondansetron/dexamethasone (D1)
Number of subjects: 304
Study 33710814 — intervention group
Group type: COMPARATOR
Intervention: aprepitant/ondansetron/dexamethasone (D1-3)
Number of subjects: 304
Study 33710814 — intervention group
Group type: COMPARATOR
Intervention: aprepitant/ondansetron/dexamethasone (D1-3) with olanzapine
Number of subjects: 304
Study 33710814 — intervention group
Group type: COMPARATOR
Intervention: aprepitant/ondansetron/dexamethasone (D1)
Number of subjects: 304
Study 32115470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 35
Study 32115470 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 35
Study 34438361 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg saffron extract (affron®)
Number of subjects: 120
Study 34438361 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 mg saffron extract (affron®)
Number of subjects: 120
Study 34438361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34438361 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron supplementation
Number of subjects: 120
Study 32155616 — intervention group
Group type: EXPERIMENTAL
Intervention: Basil essential oil 2%, 4%, 6%
Number of subjects: 144
Study 32155616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 36435760 — intervention group
Group type: EXPERIMENTAL
Intervention: iAssist system (hand-held navigation)
Number of subjects: 60
Study 36435760 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 60
Study 36435760 — intervention group
Group type: EXPERIMENTAL
Intervention: iAssist system
Number of subjects: 60
Study 34460973 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg daily)
Number of subjects: 72
Study 34460973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 34357880 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 500
Study 34357880 — intervention group
Group type: COMPARATOR
Intervention: Platelet-Poor Plasma (PPP)
Number of subjects: 500
Study 34357880 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP irrigation
Number of subjects: 500
Study 34357880 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 500
Study 32472928 — intervention group
Group type: EXPERIMENTAL
Intervention: High-heat capacity mattress (MAT)
Number of subjects: 19
Study 32472928 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 19
Study 32472928 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 19
Study 32472928 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed running distance
Number of subjects: 19
Study 32472928 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary collisions
Number of subjects: 19
Study 34259904 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline as an add-on to thrombolytic therapy
Number of subjects: 0
Study 34259904 — intervention group
Group type: COMPARATOR
Intervention: Placebo as an add-on to thrombolytic therapy
Number of subjects: 0
Study 33407269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ml/kg Formulaid™ (100 mg/kg of ARA and 50 mg/kg of DHA)
Number of subjects: 120
Study 33407269 — intervention group
Group type: COMPARATOR
Intervention: 0.4 ml/kg MCT‐oil™ (medium chain triglycerides)
Number of subjects: 120
Study 35852528 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% albumin solution
Number of subjects: 1407
Study 35852528 — intervention group
Group type: COMPARATOR
Intervention: Ringer acetate solution
Number of subjects: 1407
Study 34444817 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of CoQ10 and 20 mg of NADH once daily
Number of subjects: 207
Study 34444817 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 207
Study 32653082 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainwave entrainment
Number of subjects: 49
Study 32653082 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 35034630 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted pulmonary metastasectomy
Number of subjects: 512
Study 35034630 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 512
Study 33728845 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric rehabilitation along with standard pharmacological treatment
Number of subjects: 100
Study 33728845 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological treatment alone
Number of subjects: 100
Study 35312182 — intervention group
Group type: EXPERIMENTAL
Intervention: GPR (gamma-glutamyl transpeptidase-to-platelet ratio) with a cutoff of <0.35
Number of subjects: 880
Study 35312182 — intervention group
Group type: COMPARATOR
Intervention: APRI (aspartate aminotransferase-to-platelet ratio index)
Number of subjects: 880
Study 35312182 — intervention group
Group type: COMPARATOR
Intervention: FIB-4 (fibrosis-4 scoring system)
Number of subjects: 880
Study 34886576 — intervention group
Group type: EXPERIMENTAL
Intervention: Yelling intervention during Coriolis stimulation (5-8 times yelling)
Number of subjects: 42
Study 34886576 — intervention group
Group type: COMPARATOR
Intervention: Control trial (keeping quiet during each minute of rotation)
Number of subjects: 42
Study 34886576 — intervention group
Group type: EXPERIMENTAL
Intervention: Yelling intervention during Coriolis stimulation
Number of subjects: 42
Study 33180150 — intervention group
Group type: EXPERIMENTAL
Intervention: ECLS (Extracorporeal Life Support)
Number of subjects: 42
Study 33180150 — intervention group
Group type: COMPARATOR
Intervention: Control (no ECLS)
Number of subjects: 42
Study 32412900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium triple viable capsule therapy
Number of subjects: 36
Study 32412900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 36
Study 32412900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low-fat diet and Bifidobacterium triple viable capsule therapy
Number of subjects: 36
Study 32412900 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 36
Study 35041159 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg/month (240 mg loading dose)
Number of subjects: 462
Study 35041159 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 462
Study 35041159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 33504485 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 1755
Study 33504485 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 1755
Study 33504485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1755
Study 33504485 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg biweekly
Number of subjects: 1755
Study 32882036 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral octreotide capsules (OOCs)
Number of subjects: 56
Study 32882036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 34931667 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 µg RSVpreF
Number of subjects: 0
Study 34931667 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 µg RSVpreF
Number of subjects: 0
Study 34931667 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 µg RSVpreF
Number of subjects: 0
Study 34931667 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF with SIIV
Number of subjects: 0
Study 34931667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34508805 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy responders (n = 21)
Number of subjects: 80
Study 34508805 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation/supportive therapy responders (n = 6)
Number of subjects: 80
Study 34508805 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 80
Study 33892670 — intervention group
Group type: EXPERIMENTAL
Intervention: PDLASTA® (Pegfilgrastim) - single subcutaneous dose
Number of subjects: 80
Study 33892670 — intervention group
Group type: COMPARATOR
Intervention: PDGRASTIM® (Filgrastim) - repeated six daily injections
Number of subjects: 80
Study 36293977 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor climbing (IG), 2 times per week for 10 months
Number of subjects: 0
Study 36293977 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor climbing (IG) for females
Number of subjects: 0
Study 36293977 — intervention group
Group type: COMPARATOR
Intervention: Sports programme (CGI)
Number of subjects: 0
Study 36293977 — intervention group
Group type: COMPARATOR
Intervention: Control group (CGII)
Number of subjects: 0
Study 33833090 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - three individual sessions
Number of subjects: 40
Study 33833090 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI)
Number of subjects: 40
Study 34811374 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at moderate intensity (10-min session on a treadmill at 50%)
Number of subjects: 26
Study 34811374 — intervention group
Group type: COMPARATOR
Intervention: Control (resting session)
Number of subjects: 26
Study 32720550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 15
Study 32720550 — intervention group
Group type: COMPARATOR
Intervention: Neutrally Adjusted Ventilatory Assist (NAVA)
Number of subjects: 15
Study 35055694 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 90
Study 35055694 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose administered orally
Number of subjects: 90
Study 35055694 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Number of subjects: 90
Study 35055694 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability
Number of subjects: 90
Study 33482045 — intervention group
Group type: EXPERIMENTAL
Intervention: Grounded flaxseed (GF) 30 gr/day
Number of subjects: 90
Study 33482045 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FO) 10 gr/day
Number of subjects: 90
Study 33482045 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 32873290 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day for 3 days
Number of subjects: 40
Study 32873290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35265174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic detection based on the random forest segmentation algorithm
Number of subjects: 100
Study 35265174 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasonic detection
Number of subjects: 100
Study 35265174 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear osmotic pressure
Number of subjects: 100
Study 33795567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-dye laser followed by fractional ablative CO2 laser-assisted delivery of betamethasone-calcipotriol gel
Number of subjects: 22
Study 33795567 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated hand)
Number of subjects: 22
Study 33299395 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Body‐Mind Training (IBMT), 10 hours of mindfulness training
Number of subjects: 0
Study 33299395 — intervention group
Group type: COMPARATOR
Intervention: Active control - relaxation training (RT)
Number of subjects: 0
Study 35215521 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (one serving of supplementary food, Nestle Sinlac, for 3 months)
Number of subjects: 38
Study 33847325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 24 weeks
Number of subjects: 624
Study 33847325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 52 weeks
Number of subjects: 624
Study 33847325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 624
Study 33847325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 32318744 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily for 28 days
Number of subjects: 1522
Study 32318744 — intervention group
Group type: COMPARATOR
Intervention: Vehicle, applied twice daily for 28 days
Number of subjects: 1522
Study 36317518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan (50, 100, or 200 mg)
Number of subjects: 24
Study 36317518 — intervention group
Group type: COMPARATOR
Intervention: Dexlansoprazole (60 mg)
Number of subjects: 24
Study 33835026 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite urban sanitation intervention (pour-flush toilets with septic tanks)
Number of subjects: 0